JAK2 and diffuse large B-cell lymphoma: Thus, when we divided DLBCL patients into three subgroups (DLBCL_JAK2/PD-L2_amp, DLBCL_MYD88_L265P and DLBCL_others, both DLBCL_JAK2/PD-L2_amp and DLBCL_MYD88_L265P demonstrated dismal OS and PFS with a median follow-up of 9 "years, as compared with DLBCL_others.